Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,433.56
(
-0.90%
)
US TECH 100
28,470.00
(
-1.12%
)
Dow Jones
49,656.88
(
-0.81%
)
Brent Oil
106.45
(
2.17%
)
Bitcoin
79,384.47
(
-2.06%
)
News Focus
News Focus
Post# of 257575
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122986
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: zipjet post# 59208

Sunday, 02/17/2008 5:00:25 PM

Sunday, February 17, 2008 5:00:25 PM

Post# of 257575
>But for Copaxone to have ANY value for MNTA shareholders three things must happen. 1 - It must not be eliminated by a better drug/s. (Considering the marginal benefit of Copaxone, they could be displaced completely.) 2 - The company must stay viable. (That means mL or M118 needs to come through.) 3 - The company must stay independent - not bought out.<

I disagree on #3; clearly, a buyout offer for the whole company can incorporate an implicit valuation for the Copaxone program.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Unleash the power of Level 2

Spot liquidity moves with access to US order books.

Sign Up